Effect of magnesium sulfate on induced opiate- withdrawal syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190207042648N1

Enrollment

Registered

2019-05-22

Start date

2019-03-21

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

withdrawal of opiate. Mental and behavioural disorders due to use of opioids withdrawal state

Interventions

Intervention 1: Intervention group: patients with induced opiate withdrawal. they will treated by magnesium sulfate 3gr Iv Infusion in 20 min stat & 10 mg/kg/h Iv Infusion for 3 hours in addition s

Eligibility

Sex/Gender

All

Age

14 Years to 40 Years

Inclusion criteria

Inclusion criteria: patients with Induced opiate withdrawal syndrome

Exclusion criteria

Exclusion criteria: Naloxane induced withdrawal Ischemic heart disease renal failure Hepatic failure Uncontrolled hypertension. AIDS Cerebrovascular disease long-term treatment with calcium Chanel blocker Diabetic neuropathy. Allergy to magnesium compounds Concomitant use of other substances such as methamphetamine, alcohol or other stimulants Asthma. In case of incomplete registration ,Lack of patient collaboration and patient inaccessibility (in providing required information) Pregnancy

Design outcomes

Primary

Measure	Time frame
Opiate withdrawal score. Timepoint: at start and 0.5 and 2 hours after treatment. Method of measurement: By Opiate withdrawal scale.;MG serum level. Timepoint: start and after 2 hours. Method of measurement: MG serum level.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Moshiri

Mashhad University of Medical Sciences

Moshirimo@gmail.com+98 51 3802 2515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026